Medidata appoints Pascal Daloz and Michael Pray to its senior leadership

Pascal Daloz, Chief Executive Officer at Medidata

Medidata, a Dassault Systèmes company, announced a new leadership structure designed to fuel its mission of creating solutions that power smarter treatments and healthier people. It is an opportunity to further growth to enhance clients’ ability to unlock greater value across the Dassault Systèmes portfolio, taking drug development to new heights.

What do the appointees bring to Medidata in the roles?

Pascal Daloz, an accomplished leader at Dassault Systèmes, was named CEO of Medidata. Daloz played a key role in the success of the acquisition of Medidata in 2019, and his proven success as a business leader and visionary are a great complement to Medidata.

Michael Pray was named company COO. In his prior role as Medidata Chief Commercial Officer, he was instrumental in the rapid growth of the company, which includes more than doubling total revenue to over $1bn and 100% growth in number of customers during the last six years. Pray will lead the day-to-day operations at Medidata, and will work closely with Daloz to build a complete solution set serving the life sciences industry at large.

What do the appointments mean for Medidata?

“Customers are asking to do more with Medidata, and we are evolving to meet their digital transformation needs,” commented Pascal Daloz, Chief Executive Officer at Medidata.

“Building on the strong foundation set over the last twenty years, we will continue to pioneer unmatched solutions across the life sciences lifecycle. We are committed to this industry and will invest to achieve the vision that includes prevention to precision medicine and discovery to distribution, in order to be at the center of every patient journey.”

Medidata is a subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is set to lead the digital transformation of life sciences in the age of personalized medicine with the first scientific and business platform, from research to commercialization.